by admin_63069 | May 16, 2022 | Articles of Interest
Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.
by admin_63069 | May 12, 2022 | Articles of Interest
Improved screening to reduce over diagnosis and over treatment of prostate cancer
by admin_63069 | May 8, 2022 | Articles of Interest
Insurance company contributed to settlement without insured’s consent.
by admin_63069 | May 4, 2022 | Articles of Interest
Click to read findings of Weill Cornell Medicine, published March 22 in the Journal of the National Cancer Institute.
by admin_63069 | Apr 30, 2022 | Articles of Interest
Genetic determinants of PSA proved to robustly predict prostate cancer diagnoses and improve the detection of aggressive disease; however, larger and more diverse studies are still required.
by admin_63069 | Apr 26, 2022 | Articles of Interest
Read this perspective shared by a prostate cancer survivor
